Search results
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 2 days agoOn Monday, Deutsche Bank reiterated a Hold rating and a price target of GBP110.00 on stock of ...
BMO maintains target on AstraZeneca shares, cites trial success By Investing.com
Investing.com· 2 days agoOn Wednesday, BMO Capital upheld its Outperform rating on AstraZeneca (NASDAQ:AZN) with a steady...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 4 days agoAstrazeneca (AZN) closed the most recent trading day at $78.99, moving +1.24% from the previous...
Data Science Hiring Process at AstraZeneca
Analytics India Magazine· 2 days agoWith over 45 years of presence in India, British-Swedish pharmaceutical and biotechnology giant AstraZeneca has data science and AI capabilities deeply ingrained across its ...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 5 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 4 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 3 days agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 4 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 5 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
AstraZeneca finalizes Fusion Pharmaceuticals buyout By Investing.com
Investing.com· 3 days agoThis move is aligned with AstraZeneca (NASDAQ:AZN)'s strategy to advance cancer therapy by focusing...